Kura Oncology KURA Commercialization Services — Contract With Customer Liability Current
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
As of March 31, 2026, the remaining unrecognized consideration allocated to the development services for monotherapy was $27.0 million and to the development services in combination with other therapies was $161.7 million. As of March 31, 2026, $275.7 million of consideration allocated to commercialization services and profit and loss sharing payments received or expected to be received, was constrained and included in contract liabilities, of which $2.0 million was classified as current, and $273.7 million was classified as long-term.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's commercialization services — contract with customer liability current?
- Kura Oncology (KURA) reported commercialization services — contract with customer liability current of $2M in Q1 2026.
- What does commercialization services — contract with customer liability current mean?
- Reflects the portion of deferred revenue from commercialization services that is expected to be recognized as revenue within the next twelve months. This liability arises when the company receives consideration from a customer before the associated performance obligations are satisfied. It serves as a measure of short-term service delivery commitments.
Ask your AI about Kura Oncology's commercialization services — contract with customer liability current.
Connect your AI assistant and compare it to peers, right in your chat.
